
PMC:7335653 / 1158-1785
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T11 | 21-26 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T12 | 71-78 | Body_part | denotes | hormone | http://purl.org/sig/ont/fma/fma12278 |
T13 | 252-261 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
T14 | 271-275 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T26 | 199-201 | Disease | denotes | HP | http://purl.obolibrary.org/obo/MONDO_0004553 |
T27 | 390-406 | Disease | denotes | hypersensitivity | http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271 |
T29 | 512-521 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T16 | 15-26 | http://purl.obolibrary.org/obo/CLO_0053065 | denotes | human cells |
T17 | 152-155 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T18 | 199-201 | http://purl.obolibrary.org/obo/CLO_0003797 | denotes | HP |
T19 | 199-201 | http://purl.obolibrary.org/obo/PR_000008725 | denotes | HP |
T20 | 206-207 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T21 | 312-314 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
T22 | 608-609 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T6 | 71-78 | Chemical | denotes | hormone | http://purl.obolibrary.org/obo/CHEBI_24621 |
T7 | 79-93 | Chemical | denotes | glucocorticoid | http://purl.obolibrary.org/obo/CHEBI_24261 |
T8 | 149-151 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756|http://purl.obolibrary.org/obo/CHEBI_8378 |
T10 | 190-194 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T11 | 199-201 | Chemical | denotes | HP | http://purl.obolibrary.org/obo/CHEBI_74055 |
T12 | 271-273 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T14 | 277-279 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T16 | 301-310 | Chemical | denotes | biomarker | http://purl.obolibrary.org/obo/CHEBI_59163 |
T17 | 346-348 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756|http://purl.obolibrary.org/obo/CHEBI_8378 |
T19 | 438-456 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
T20 | 470-472 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756|http://purl.obolibrary.org/obo/CHEBI_8378 |
T22 | 624-626 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756|http://purl.obolibrary.org/obo/CHEBI_8378 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 0-11 | http://purl.obolibrary.org/obo/GO_0042592 | denotes | Homeostasis |
T9 | 47-56 | http://purl.obolibrary.org/obo/GO_0046903 | denotes | secretion |
T10 | 390-406 | http://purl.obolibrary.org/obo/GO_0002524 | denotes | hypersensitivity |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T7 | 199-201 | Phenotype | denotes | HP | http://purl.obolibrary.org/obo/HP_0006516 |
T8 | 390-406 | Phenotype | denotes | hypersensitivity | http://purl.obolibrary.org/obo/HP_0041092 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 0-148 | Sentence | denotes | Homeostasis of human cells is regulated by the secretion of the stress hormone glucocorticoid, to varying degrees, under different external stimuli. |
T12 | 149-218 | Sentence | denotes | PD has been the most effective and safer drug for HP for a long time. |
T13 | 219-316 | Sentence | denotes | It can strongly suppress several cytokines, such as IL-1, IL-6, TNF-α, and type-2 biomarker [34]. |
T14 | 317-461 | Sentence | denotes | Further, the short course of PD does not lower the overall immunity, and hypersensitivity reactions are less common than methylprednisolone [5]. |
T15 | 462-627 | Sentence | denotes | If oral PD is administered at an earlier stage of infection, fewer side effects will develop, since the inflammatory cascade might be overcome at a lower dose of PD. |